High seroreactivities to orthoebolaviruses in rural Cameroon: a case-control study on non-human primate bites and a cross-sectional survey in rural population.

Cameroon Central Africa Ebolavirus Filoviridae Pygmy Serologic Tests Sudan virus

Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
10 Aug 2024
Historique:
received: 07 06 2024
revised: 05 08 2024
accepted: 08 08 2024
medline: 10 8 2024
pubmed: 10 8 2024
entrez: 10 8 2024
Statut: aheadofprint

Résumé

Ebola (EBOV) and Sudan (SUDV) orthoebolaviruses are responsible for lethal haemorrhagic fever outbreaks in humans in Central and West Africa, and in apes that can be at the source of human outbreaks for EBOV. To assess the risk of exposure to orthoebolaviruses through contact with non-human primates (NHP), we tested the presence of antibodies against different viral proteins with a microsphere-based multiplex immunoassay in a case-control study on bites from NHPs in forest areas from Cameroon (n=795), and in cross-sectional surveys from other rural populations (n=622) of the same country. Seroreactivities against at least two viral proteins were detected in 13% and 12% of the samples for EBOV and SUDV, respectively. Probability of seroreactivity was not associated with history of NHP bites, but was three times higher in Pygmies compared to Bantus. Although no neutralizing antibodies to EBOV and SUDV were detected in a selected series of highly reactive samples, avidity results indicate strong affinity to SUDV antigens. The detection of high level of seroreactivities against orthoebolaviruses in rural Cameroon where no outbreaks have been reported, raises the possibilities of silent circulation of orthoebolavirus, or of other not yet documented filoviruses, in these forested regions.

Sections du résumé

BACKGROUND BACKGROUND
Ebola (EBOV) and Sudan (SUDV) orthoebolaviruses are responsible for lethal haemorrhagic fever outbreaks in humans in Central and West Africa, and in apes that can be at the source of human outbreaks for EBOV.
METHODS METHODS
To assess the risk of exposure to orthoebolaviruses through contact with non-human primates (NHP), we tested the presence of antibodies against different viral proteins with a microsphere-based multiplex immunoassay in a case-control study on bites from NHPs in forest areas from Cameroon (n=795), and in cross-sectional surveys from other rural populations (n=622) of the same country.
RESULTS RESULTS
Seroreactivities against at least two viral proteins were detected in 13% and 12% of the samples for EBOV and SUDV, respectively. Probability of seroreactivity was not associated with history of NHP bites, but was three times higher in Pygmies compared to Bantus. Although no neutralizing antibodies to EBOV and SUDV were detected in a selected series of highly reactive samples, avidity results indicate strong affinity to SUDV antigens.
CONCLUSION CONCLUSIONS
The detection of high level of seroreactivities against orthoebolaviruses in rural Cameroon where no outbreaks have been reported, raises the possibilities of silent circulation of orthoebolavirus, or of other not yet documented filoviruses, in these forested regions.

Identifiants

pubmed: 39126336
pii: 7731304
doi: 10.1093/infdis/jiae399
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Auteurs

Jill-Léa Ramassamy (JL)

Unité d'Epidémiologie et Physiopathologie des Virus Oncogènes, Institut Pasteur, Université de Paris Cité, CNRS UMR 3569, 28 Rue du Dr. Roux, F-75015 Paris, France.
Unité TransVIHMI, Université de Montpellier, INSERM, Institut de Recherche pour le Développement, Montpellier, France.

Ahidjo Ayouba (A)

Unité TransVIHMI, Université de Montpellier, INSERM, Institut de Recherche pour le Développement, Montpellier, France.

Guillaume Thaurignac (G)

Unité TransVIHMI, Université de Montpellier, INSERM, Institut de Recherche pour le Développement, Montpellier, France.

Chanceline Bilounga Ndongo (C)

Direction de la lutte contre les Maladies, les Epidémies et les Pandémies. Ministère de la Santé Publique, Yaoundé, Cameroun.
Faculté de Médecine et des Sciences Pharmaceutiques de l'Université de Douala, Cameroun.

Patrick Nnuka (P)

Direction de la lutte contre les Maladies, les Epidémies et les Pandémies. Ministère de la Santé Publique, Yaoundé, Cameroun.

Edouard Betsem (E)

Université de Yaoundé I, Yaoundé, Cameroun.

Richard Njouom (R)

Centre Pasteur du Cameroun, Unité de Virologie, Yaoundé, Cameroun.

Eitel Mpoudi Ngole (E)

Laboratoire de Virologie, CREMER/IMPM, Yaoundé, Cameroun.

Jessica Vanhomwegen (J)

Unité Environnement et Risques Infectieux, Institut Pasteur, 75015 Paris, France.

Damien Hoinard (D)

Unité Environnement et Risques Infectieux, Institut Pasteur, 75015 Paris, France.

Patrick England (P)

Plateforme de Biophysique Moléculaire, C2RT, Institut Pasteur, CNRS UMR3528, Paris, France.

Alexandra Journeaux (A)

Unit of Biology of Emerging Viral Infections, Institut Pasteur, Lyon, France.
National Reference Center for Viral Hemorrhagic Fevers, Lyon, France.

Caroline Picard (C)

Unit of Biology of Emerging Viral Infections, Institut Pasteur, Lyon, France.
National Reference Center for Viral Hemorrhagic Fevers, Lyon, France.

Damien Thomas (D)

National Reference Center for Viral Hemorrhagic Fevers, Lyon, France.
Laboratoire P4 Jean Mérieux INSERM, US003, INSERM, Lyon, France.

Delphine Pannetier (D)

National Reference Center for Viral Hemorrhagic Fevers, Lyon, France.
Laboratoire P4 Jean Mérieux INSERM, US003, INSERM, Lyon, France.

Sylvain Baize (S)

Unit of Biology of Emerging Viral Infections, Institut Pasteur, Lyon, France.
National Reference Center for Viral Hemorrhagic Fevers, Lyon, France.

Eric Delaporte (E)

Unité TransVIHMI, Université de Montpellier, INSERM, Institut de Recherche pour le Développement, Montpellier, France.

Martine Peeters (M)

Unité TransVIHMI, Université de Montpellier, INSERM, Institut de Recherche pour le Développement, Montpellier, France.

Antoine Gessain (A)

Unité d'Epidémiologie et Physiopathologie des Virus Oncogènes, Institut Pasteur, Université de Paris Cité, CNRS UMR 3569, 28 Rue du Dr. Roux, F-75015 Paris, France.

Classifications MeSH